Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Study Evaluating the Safety of ABT-263 in Combination With Rituximab in Subjects With CD20-positive Lymphoid Malignancies

NCT00788684 is registered in ClinicalTrials.gov with AbbVie as lead sponsor.

NCT NCT00788684
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00788684 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Study Evaluating the Safety of ABT-263 in Combination With Rituximab in Subjects With CD20-positive Lymphoid Malignancies
Lead sponsor
AbbVie
Phase
Phase 1
Overall status
Completed
Start date
July 21, 2009
Completion date
February 7, 2025
Enrollment
29 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

cd20-positive lymphoid malignancies, chronic lymphoid leukemia, hematological malignancies, non-hodgkin's lymphoma